Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM

Prior treatment

• Receipt of bevacizumab within 3 months prior to physician-investigator confirmation of eligibility.

Other illness

• Active hepatitis B or hepatitis C infection.
• Any other active, uncontrolled infection.
• Class III/IV cardiovascular disability according to the New York Heart Association Classification
• Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10 mg daily of prednisone. Patients with autoimmune neurological diseases (such as MS or Parkinson's) will be excluded.

Lab values

• History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).

Other

• Tumors primarily localized to the brain stem or spinal cord.
• Severe, active co-morbidity in the opinion of the physician-investigator that would preclude participation in this study.
• Patients who are pregnant or nursing (lactating).

• Signed, written informed consent
• Male or female age ≥ 18 years
• Patients with glioblastoma, IDH-wildtype (as defined by WHO 2021 Classification of CNS Tumors) that has recurred following prior radiotherapy1. For patients with tumors harboring methylation of the MGMT promoter, a t l east 1 2 w eeks must have elapsed since completion of first-line radiotherapy.
• Tumor tissue positive for wild-type EGFR amplification by NeoGenomics Laboratories. Archival tumor from patient's initial surgery at time of original diagnosis or recently collected tumor from time of recurrence are acceptable.
• Surgical tumor resection for disease control/management (Arms A, B, C) or tumor biopsy to confirm tumor recurrence (Arms A and B only) is clinically indicated in the opinion of the physician-investigator.
• Adequate organ function defined as:
  • Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 30 ml/min and not on dialysis.
  • ALT/AST ≤ 3 x ULN
  • Total bilirubin ≤ 2.0 mg/dL, except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome (≤ 3.0 mg/dL)
  • Left Ventricular Ejection Fraction (LVEF) ≥ 45% confirmed by ECHO/MUGA
  • Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen \> 92% on room air
• Karnofsky Performance Status ≥ 60%.
• Subjects of reproductive potential must agree to use acceptable birth control methods, as described in protocol Section 4.3.